2024 European Breast Cancer Conference

By Caroline Helwick / September 25, 2024 / 2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phas...

Breast Cancer

Genomics/Genetics

By Caroline Helwick / July 25, 2024 / 2024 European Breast Cancer Conference

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently bei...

2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC